This study reports the development of novel drug delivery complexes self-assembled by divalent metal ion-assisted coacervation for controlled and sustained release of a hydrophilic small drug molecule minocycline hydrochloride (MH). MH is a multifaceted agent that has demonstrated therapeutic effects in infection, inflammation, tumor, as well as cardiovascular, renal, and neurological disorders due to its anti-microbial, anti-inflammatory, and cytoprotective properties. However, the inability to translate the high doses used in experimental animals to tolerable doses in human patients limits its clinical application. Localized delivery can potentially expose the diseased tissue to high concentrations of MH that systemic delivery cannot achieve, while minimizing the side effects from systemic exposure. The strong metal ion binding-assisted interaction enabled high drug entrapment and loading efficiency, and stable long term release for more than 71 d. Released MH demonstrated potent anti-biofilm, anti-inflammatory, and neuroprotective activities. Furthermore, MH release from the complexes is pH-sensitive as the chelation between minocycline and metal ions decreases with pH, allowing 'smart' drug release in response to the severity of pathology-induced tissue acidosis. This novel metal ion binding-mediated drug delivery mechanism can potentially be applied to other drugs that have high binding affinity for metal ions and may lead to the development of new delivery systems for a variety of drugs.
Introduction
Minocycline hydrochloride (MH) is a tetracycline derivative antibiotic that also has anti-inflammatory, anti-oxidative, and anti-apoptotic properties [1] . It is commonly used clinically to treat infection and inflammation [1] [2] [3] [4] . In addition, studies have shown that by attenuating the expression of matrix metalloproteases, MH could inhibit smooth muscle cell proliferation and neointimal hyperplasia after arterial injury [5] , and reduce tumor expansion and migration [6] . MH also demonstrated cytoprotective properties in the cardiovascular, renal, and central nervous systems [7] . It has been shown to protect cardiac myocytes against ischemia-reperfusion injury and ameliorate cardiac dysfunction and cell loss [8, 9] , reduce cell apoptosis and inflammation in ischemic renal diseases [10] , and exert neuroprotective effects in various neurological disorders including stroke [11] , spinal cord injury [12] , Parkinson's disease [13] , multiple sclerosis [14] , amyotrophic lateral sclerosis [15] and Alzheimer's disease [16] .
Many of these diseases require continuous and high concentrations of MH treatment at dose levels much higher than the standard human dose of 3 mg kg −1 [17] . For example, to inhibit tumor growth in mice, systemic administration of 60-120 mg kg
MH was required for 4 weeks [18] ; to reduce neointima formation after artery injury, animals need to receive intraperitoneal injections of 70-100 mg kg
MH for 16 d [5] ; to reduce neuronal death and improve functional outcome in animal models of multiple sclerosis and Parkinson's disease, 3-4 weeks of MH treatment at a dose of 45 mg kg −1 was required [13, 14] . However, systemic administration of high doses of MH for extended period of time has been shown to cause morbidity, liver toxicity and even death in experimental animals [5, 12] . Thus, localized delivery of MH can potentially expose the diseased tissue to high concentrations of MH while minimizing the deleterious side effects from systemic exposure. However, current drug delivery systems are not ideal for local delivery of bioactive MH for an extended period of time. MH is a small molecule drug (MW 494 Da) with high water solubility. Therefore it is released very quickly (less than 24 h) from hydrophilic drug delivery systems [19] [20] [21] . Furthermore, while hydrophobic poly(lactic-co-glycolic acid) (PLGA) microspheres [2, 22] or nanoparticles [23] have been used as drug carriers for MH encapsulation and release, the acidic degradation products of PLGA can reduce local tissue pH and subsequently elicit host inflammation [24, 25] . In addition, MH diffuses into the aqueous phase easily due to its high water solubility, leading to low loading efficiency (up to 1.92%) of MH in the PLGA particles [23] .
In this study we developed novel MH-encapsulated complexes based on metal ion binding-mediated interaction for sustained local delivery of bioactive MH. MH can chelate multivalent metal ions such as Ca 2+ and Mg 2+ to form positively charged chelates without affecting its biological activities [26] . Dextran sulfate (DS), a biocompatible polysaccharide, also has high binding affinity for divalent metal ions such as Ca 2+ and Mg 2+ ions [27] . Our lab has previously discovered that Ca 2+ ions could be used as linkers to attach MH to DS in a layer-by-layer fashion [28] . Utilizing this property, we developed an electrostatic layer-by-layer thin film coating using DS + Ca
2+
, MH, and gelatin type A as building blocks. While the coating can be used on implanted medical devices for local delivery of MH, they are not readily used in applications where implanted devices are not involved. In the present study, we discovered that DS and MH can form insoluble complex in the presence of Ca 2+ or
Mg

2+
. It is noteworthy that unlike conventional coacervation where two oppositely charged polymers are required to form the complex [29] , in our system only one charged polymer (DS) is required for complex formation. MH is electrically neutral in the pH range of complex formation (5.5-6.5). This is the first time that metal ion binding-assisted interaction is used to induce insoluble complex formation between a charged polymer and a neutral small drug molecule, which enables high drug entrapment efficiency (more than 96.9%), high drug loading efficiency (around 45%), and stable long term release for more than 71 d. In this study, we investigated the parameters that control MH loading and release, and examined the pHsensitive release behavior of MH from the complexes. Further, the bioactivity of released MH including antibacterial, anti-inflammatory, and neuroprotective potencies was assessed. This novel drug delivery system is highly promising for long-term local delivery of MH for a variety of clinical applications.
Materials and methods
Materials
All the chemicals, unless otherwise specified, were obtained from Sigma-Aldrich and used without further purification. Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923) strains were purchased from American Type Culture Collection (ATCC, Manassas, VA). A multi-drug resistant Acinetobacter baumannii clinical isolate was locally isolated from a hospitalized patient having invasive infection following a protocol approved by the Institutional Review Board of Drexel University.
Preparation of MH-metal ion-DS complex
Dextran sulfate (500 kDa) was dissolved in CaCl 2 or MgCl 2 solution at different concentrations to study the effect of metal ion concentration on MH loading and release. Minocycline solution (2 mg ml
) was prepared in deionized (DI) water. 150 μl DS solution was mixed with equal volume of MH solution and vortexed for 10 s to induce complex formation. The complex was collected by centrifugation at 10 000 rpm for 10 min and washed three times with DI water. For zeta potential measurement the complexes were re-suspended in 1 ml DI water after washing and analyzed using a Malvern Nano ZS90 zeta-sizer (Westborough, MA, USA).
For SEM sample preparation, 10 μl complex suspension was spread on a silicon wafer and lyophilized. The silicon wafer was mounted on an aluminum stub, sputtered with 10 nm Pt-Pd and viewed with a Zeiss Supra 50VP SEM at an operating voltage of 5 kV.
Entrapment efficiency and loading efficiency
The amount of MH and DS loaded in the complex was determined by subtracting the amount of MH and DS remaining in the supernatant from the initial amount of MH and DS added in the solution for complex formation. The concentration of MH in the supernatant was measured by UV-vis spectroscopy at 245 nm (DS have negligible absorbance at this wavelength). DS concentration in the supernatant was determined by titration of sulfate groups with the cationic dye toluidine blue [30] . The entrapment efficiency of MH in the DS-MH complexes was calculated as the ratio of the weight of MH encapsulated in the complex to the total weight of MH added in the solution. The loading efficiency of MH in the DS-MH complexes was calculated as the ratio of the weight of MH encapsulated in the complex to the total weight of the complex.
Quantification of MH release
The complexes encapsulating 300 μg MH were incubated at 37°C in 300 μl of Hank's balanced salt solution (HBSS) for quantification of MH release. The release medium was changed every 24 h till drug release was completed. The amount of MH released every 24 h was determined by UV absorbance at 245 nm. For quantification of MH release in HBSS supplemented with bovine serum albumin (BSA), the amount of released MH was determined by UV absorbance at 380 nm (DS and BSA have negligible absorbance at this wavelength).
2.6. Anti-inflammatory bioactivity of released MH RAW264.7 murine macrophages (kindly provided by Dr Narayan Avadhani, University of Pennsylvania) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. The cells were seeded in 96-well tissue culture plates at a density of 60 000 cells per well. 24 h after seeding, the cells were stimulated with 400 pg ml −1 lipopolysaccharide (LPS), a potent proinflammatory endotoxin, and treated with MH that was released during a 24 h period and diluted to 0.5 μg ml ). The biofilms were allowed to set by incubating at 37°C in a stationary incubator for 24 h. For quantification of bacterial viability, the wells were washed three times with sterile PBS to remove loose planktonic cells, and incubated with 200 μl of XTT reagent in the dark at 37°C for 2 h. The metabolic conversion of XTT into orange-colored product was measured photometrically at 492 nm using a microtiter plate reader (BioTek). Only surviving/live bacterial cells show evidence of respiration and metabolize XTT reagent to reduce it to an orange colored soluble product [31] . For visualization of live and dead bacteria, the cells were stained with LIVE/ DEAD BacLight Bacterial Viability kit (Invitrogen), and examined by EVOS FL color imaging system (AMG).
Neuroprotection by released MH
Rat cortical neurons were isolated from E17 rat embryos in accordance with protocols approved by Drexel University's IACUC committee. The cortices were dissected, minced, and enzymatically dissociated with 0.25% trypsin and 1 mM EDTA for 2 min at 37°C. Then the tissue was triturated through a fire polished glass pipette in 5100 U ml −1 DNase in HBSS solution to obtain dissociated cells. Following centrifugation, the cells were re-suspended in neurobasal medium (Invitrogen) supplemented with 2% B27 supplement (Invitrogen) and 2 mM L-glutamine, and seeded in 48-well culture plates at a density of 120 000 cells cm
. After 7 d of culture, the culture medium was replaced with neurobasal medium supplemented with B27 minus antioxidants (AO) to remove the neuroprotective AO. The neurons were treated with 100 μM hydrogen peroxide (H 2 O 2 ), 15 μg ml ) for 6 h. Cell viability was determined using cell counting kit-8 (CCK-8, Dojindo). Finally, the cells were stained with live/dead staining (Calcein AM for live cells and ethidium homodimer for dead cells) to visualize neuron morphology and survival. Fluorescent images were captured using an inverted fluorescence microscope (Leica).
Statistical analysis
Multiple pairwise comparisons were conducted using a general linear analysis of variance (ANOVA) model and Tukey test. P < 0.05 was considered statistically significant. Data are presented as mean ± standard deviations. -based complex is unclear. MH loading in both complexes is similar (as discussed later), suggesting that the change in color is not due to different MH loading. Bioactivity assay showed that the color change did not affect the bioactivity of released MH.
The DS-MH complex suspension was collected by centrifugation. FTIR spectra (figure 2(A)) revealed that DS had an adsorption peak at 1233 cm −1 (asymmetric stretching of S=O in sulfate group) [32] -based complex, respectively. These results suggest that the sulfate and hydroxyl groups in the DS molecules interact with MH or metal ions in the complex. Figure 2 (B) shows that MH had a peak at 1583 cm −1 , corresponding to C=O stretching on C 11 [33] , which is part of a chelating site (C 10 -C 11 -C 12 ) for Ca 2+ or Mg 2+ ions (scheme 1(B)) [34] . When forming complex with DS and metal ions, this peak was shifted to 1607 cm [35] . Our previously study has shown that MH could chelate both free metal ions and metal ions that are attached to the sulfate groups in DS [28] . Thus, DS could interact with MH through metal ion binding (scheme 1(C)). One MH molecule has two metal ion binding sites as shown in scheme 1(B) (red boxes). However, although only the functional group on C 10 -C 11 -C 12 could be detected in the complexes by FTIR, we cannot rule out the possibility that the other metal ion binding site also participates in complex formation. MH has four pKa values, 5 and 9.5 for the two amine functional groups on C7 and C4, respectively, and 2.8 and 7.8 for the two hydroxyl groups at C3 and C4, respectively [36] . Thus, It is zwitterionic at the pH of complex formation (5.5-6.5) with one negatively charge from deprotonation of the hydroxyl group at C3 (pKa = 2.8) and one positive charge from the ammonium group at C4 (pKa = 9.5) [37] . The positively charged ammonium group at C4 in MH could form electrostatic interaction with the negatively charged sulfate group in DS (scheme 1(C)). Furthermore, the hydroxyl group in DS can potentially form hydrogen bonding with the hydroxyl, carbonyl and amide groups in MH (scheme 1(B), green boxes). Although MH could potentially interact with DS through electrostatic interaction and hydrogen bonding, no insoluble complex was formed when DS and MH were mixed together in the absence of metal ions. Similarly, mixing DS and metal ions together without MH did not lead to formation of insoluble complex either even though DS is known to have high binding affinity for Ca 2+ and Mg 2+ ions. [27] We speculate that for insoluble complex formation the crosslinking of DS is needed, which can only be achieved by interacting with both metal ions and MH since all three components are necessary for insoluble complex formation. We postulate that one MH molecule can interact with at least two functional groups in DS simultaneously through metal ion binding, electrostatic interaction, or hydrogen bonding to induce intra and intermolecular crosslinking of DS (scheme 1(C)), and at least one of these interactions must be metal ion binding since electrostatic interaction and hydrogen bonding are insufficient to induce insoluble complex formation between DS and MH.
Zeta potential measurement ( figure 3(A) ) shows that the complexes remained negatively charged over a wide range of DS/MH mass ratio from 0.3 to 1.8. Little complex was formed below the ratio of 0.3, and the entrapment efficiencies for both MH and DS reached peak at the ratio of 1.2 (figures 4(B) and (D)), after which MH loading reached plateau. Thus, within the ratio range of effective complex formation the complex remained negatively charged.
SEM images (figures 3(B) and (C)) show that the complexes were composed of aggregated nanoparticles with size ranging from 50 to 100 nm. These complexes can be embedded in various carriers such as wound dressing, implant or implant coatings, or hydrogels for local delivery of MH depending on specific biomedical applications. For example, studies have shown that intrathecal injection of drug-loaded hydrogel can bypass the diffusive barrier presented by the pia mater and has been shown to be safe and effective to deliver drugs to the spinal cord tissue [38] [39] [40] [41] . Our laboratory is investigating using injectable hydrogel loaded with MH-containing complexes for local delivery of MH to provide neruoprotection for spinal cord repair.
We investigated the effects of metal ion concentration and DS/MH mass ratio on the encapsulation efficiency. As shown in figure 4(A) , for Ca 2+ -based complex the encapsulation efficiencies for both MH and DS increased rapidly with increasing Ca 2+ concentration till 3.6 mM (94.7 ± 0.7% and 94.4 ± 0.6%), after which further increasing Ca 2+ concentration to 7.2 mM only slightly increased the encapsulation efficiencies of MH and DS to 96.9 ± 0.2% and 97.8 ± 0.1%, respectively. Figure 4 (C) demonstrates that for Mg 2+ -based complex the encapsulation efficiencies of MH and DS versus Mg 2+ concentration showed a similar pattern, except that they reached plateau (98.5 ± 0.2% and 99.4 ± 0.3%) at 5.4 mM. Further increasing Mg 2+ concentration to 7.2 mM had little effect on the encapsulation efficiencies of MH and DS (98.0 ± 0.4% and 99.4 ± 0.1%). It is likely that increasing metal ion concentration at the beginning allowed more metal ions to bind to DS molecules which subsequently increased MH loading through metal ion binding. When metal ion binding reached saturation, then further increasing metal ion concentration could not increase MH loading in the complex anymore. This result supports our hypothesis that divalent metal ions play an important role in DS and MH encapsulation into the complex. When the encapsulation efficiencies of MH and DS versus metal ion concentration reached plateau, the loading efficiency of MH reached plateau as well. When the concentration of metal ions was 7.2 mM, Ca The encapsulation efficiency is also affected by the mass ratio of DS to MH. In this study the concentration of MH was kept at 1 mg ml
. As shown in figure 4 (B), at a low DS/MH ratio of 0.1-0.3 the encapsulation efficiency of MH in Ca 2+ -based complexes was relatively low. It increased rapidly with increasing DS/MH ratio and reached plateau (96.9 ± 0.2%) at the ratio of 1.2. This result suggests that when the ratio was below 1.2 there was excess MH in the solution. In contrast, the encapsulation efficiency of DS was high (96.0 ± 1.0%) even at the low DS/MH ratio of 0.1, and it only increased slightly when further increasing the DS/MH ratio and reached peak (97.5 ± 0.1%) at the ratio of 1.2, after which the encapsulation efficiency started to decrease. This result suggests that DS became excessive when the ratio was above 1.2. The encapsulation efficiencies of MH and DS versus DS/MH ratio for Mg 2+ -based complex showed similar pattern ( figure 4(D) ) and also reached peak (98.0 ± 0.4% and 99.4 ± 0.1%) at the ratio of 1.2. Collectively, these results demonstrate that 1.2 is the optimum DS/MH ratio for complex formation.
Effect of metal ion concentration on MH release from DS-metal ion-MH complex
Since metal ions are essential for complex formation, it is possible that metal ions play an important role in mediating MH release from the complexes. Different concentrations of metal ions were used for complex formation to investigate the effect of metal ion concentration on MH release. The binding of MH or DS to metal ions is reversible. Thus, MH release from the complex could be mediated by detachment of MH-metal ion chelates from DS, or dissociation of MH from DS-bound metal ions. We have demonstrated from figure 4(A) that the encapsulation efficiency of MH in Ca -based complex, the encapsulation efficiency was increased from 89.8 ± 1.0% to 99.4 ± 0.1% when increasing Mg 2+ concentration from 3.6 to 7.2 mM. Likewise, MH release was prolonged from 41 to 71 d (figures 5(C) and (D), black line). For all the conditions, MH release followed near zero-order release kinetics after a small initial burst. Higher concentration of metal ions decreased the initial burst and prolonged the duration of release.
In the body the complex might be exposed to various types of body fluids which contain proteins. For example, when using balloon angioplasty and stenting to open the narrowed arteries the complexes could be embedded in the stent to prevent smooth muscle cell proliferation and restenosis. Under this circumstance, the complex will be exposed to blood proteins. The complex can also be embedded in hydrogel and injected into the intrathecal space between the dura mater and spinal cord tissue to promote spinal cord repair. In this case, the complexes will be exposed to cerebrospinal fluid (CSF). To study whether proteins in body fluids will interact with the complexes and alter the release profile, we added BSA in HBSS release media to more closely mimic the human body condition. Albumin was chosen because it is the most abundant protein in most body fluids. HBSS containing 0.175 and 40 mg ml −1 BSA was used to mimic CSF and blood, respectively [42, 43] . Figure 5 shows that both concentrations of BSA in the release media had little effect on MH release from Ca 2+ -or Mg
2+
-based complex, suggesting that stable MH release could be still maintained in the in vivo environment.
Effect of pH on MH release from DS-metal ion-MH complex
Acidic pH is commonly found under pathological conditions such as injury, injection, inflammation, and tumor [44] [45] [46] [47] . To simulate pathological and physiological conditions, release study was performed in HBSS at pH 6.0 and 7.4. As shown in figures 6(A) and (B), when the metal ion concentration used in complex formation was 7.2 mM, MH release from Ca 2+ -and Mg 2+ -based complexes lasted 22 and 24 d at pH 6.0, versus 55 and 71 d of stable release at physiological pH of 7.4. Studies have shown that the binding affinity of tetracycline to divalent metal ions decreases with pH [48] . Thus, reduced pH can weaken the chelation between MH and metal ions in the complex and facilitate MH release. The pH-sensitive release behavior further supports the hypothesis that reversible metal ion binding play an important role in mediating MH release from the complexes. Thus, the DS-metal ion-MH complex could be used as a 'smart' drug delivery system to actively deliver MH in response to the severity of pathology-induced tissue acidosis.
Anti-inflammatory activity of released MH
The anti-inflammatory activity of released MH was examined using the well-established macrophage cell line RAW264.7. The macrophages were stimulated with LPS for upregulating the production of NO, a cytotoxic molecule generated by macrophages in response to infection and inflammation [49] . MH as a potent anti-inflammatory drug has been shown to be able to inhibit the activation of macrophages and NO production [50] . MH released during a 24 h period on the last day of release from Ca 2+ -or Mg 2+ -based complex was diluted to 0.5 μg ml −1 and added to LPStreated macrophage cultures. The NO level in these cultures was compared to that in the culture treated with 0.5 μg ml −1 freshly prepared MH. As shown in figure 7 , MH released from either complex significantly inhibited NO production by LPS-stimulated macrophages to the same degree as fresh MH, suggesting that released MH retained the same bioactivity as fresh MH even after 55 (from Ca 2+ -based complex) or 71 (from Mg 2+ -based complex) days of release. This result indicates that this drug delivery system not only maintained the bioactivity of MH, but also released physiologically relevant amount of MH throughout the duration of release. MH degrades rapidly in aqueous solution, especially at body temperature [21] . A number of studies have shown that Ca 2+ enhances the stability of MH by forming more stable Ca 2+ -MH chelates [21, 51] .Our study demonstrated that both Ca 2+ and Mg 2+ helped to preserve the bioactivity of MH. Thus, the MH-releasing complexes hold great promise for the treatment of chronic inflammation.
Antibacterial potency of released MH
Medical implants are susceptible for bacteria adhesion and subsequent biofilm formation [52] [53] [54] [55] . Conventional systemic antibiotic therapy and the body's natural defense system are usually ineffective in killing bacteria within a biofilm [53, 55] . Following implantation the first 6 h have been identified as a 'decisive period' during which inhibition of bacterial adhesion is critical for the long-term success of an implant [53, 54] . The complex can potentially be embedded into polymer-based implants or implant coatings for local release of MH to inhibit biofilm formation during the 'decisive period'. To evaluate the antibacterial and anti-biofilm efficacies of the complexes, we selected three common bacterial species that are known to be involved in infection and biofilm formation, including A. baumannii, a strong biofilm producer that is multidrug resistant and difficult to control and treat in the healthcare setting [56] . Figure 8(A) shows that for untreated controls all three bacterial species formed biofilm after 1 d of incubation, whereas only a few bacteria were present when the cells were treated with either fresh MH, or MH released from Ca 2+ -or Mg 2+ -based complexes. XTT quantification ( figure 8(B) ) confirmed that fresh or released MH significantly inhibited biofilm formation by all three virulent pathogens, leaving negligible pathogens on the substrates. The body's defense system can easily clear the few surviving bacteria since no biofilm is formed [52] . The bacteria number in the fresh MHtreated group was not significantly different from that in the released MH-treated groups. [46] , spinal cord injury [63, 64] , and stroke [65] , initial burst release of highdose MH from the complexes can provide neuroprotection, and subsequent slow release of MH can target chronic inflammation following neural injury. For neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease which are closely associated with chronic neuroinflammation [66] , sustained local delivery of MH can potentially inhibit the progression of these debilitating diseases while obviating the side effects from long term systemic exposure. Thus, this novel drug delivery system is highly promising to be used for neural repair.
Neuroprotection by released MH
Conclusions
This study investigates novel drug delivery complexes self-assembled by divalent metal ion-assisted coacervation of MH and DS for controlled and sustained release of MH, a hydrophilic small molecule drug. This is the first time that metal ion binding is used for complex coacervation between a charged polymer and a neutral small drug molecule. We have demonstrated that the loading and release of MH can be regulated by tailoring the binding affinity between MH and DS through varying metal ion concentration. Furthermore, MH release from the complexes is pH-sensitive as the strength of chelation between MH and metal ions decreases with pH, allowing 'smart' drug release in response to the severity of pathology-induced tissue acidosis. The released MH remained bioactive throughout the duration of release because metal ions enhance the stability of minocycline by forming more stable chelates. Released MH demonstrated potent anti-biofilm, anti-inflammatory, and neuroprotective activities. The novel complex allows local delivery of high concentrations of MH that systemic delivery cannot achieve for effective treatment while avoiding the deleterious side effects from systemic exposure. Collectively, this drug delivery system has great potential to be used in a variety of clinical applications including infection, inflammation, tumor, as well as cardiovascular, renal and neural protection. Furthermore, this novel metal ion binding-mediated complex coacervation and drug delivery mechanism can potentially be employed to deliver other drugs that have a high metal ion binding affinity, and may lead to the development of new delivery vehicles for a variety of drugs. 
